Fuente: FierceBiotech After 27 years with Bavarian Nordic, including 12 as CEO, Paul Chaplin is stepping down from the helm at the Danish vaccine maker and moving back to Australia. Under his leadership, Bavarian Nordic blossomed from a small single-government-serving research company to a widespread vaccine supplier with a growing portfolio of crucial travel vaccines, such as smallpox and mpox vaccine Jynneos and chikungunya virus vaccine Vimkunya.